A major randomized trial (CaPP3) has confirmed that low-dose aspirin (100 mg/day) is just as effective as high-dose aspirin (600 mg/day) in reducing cancer risk in people with Lynch syndrome, a hereditary condition that increases colorectal cancer (CRC). The study demonstrated that the lower dose was non-inferior to the higher dose in preventing Lynch syndrome-associated cancers, including CRC and endometrial cancer, while causing significantly fewer bleeding events. This builds on previous results from the CaPP2 trial, which showed a 60% reduction in CRC risk with 600 mg aspirin. CaPP3, involving nearly 1,900 patients, found that all doses were similarly effective after five years of use, but 100 mg had the best safety profile, especially important for long-term cancer prevention. medpagetoday.com/meetingcove…